Maryanoff has been active in the fields of medicinal chemistry and organic chemistry. He is an inventor of topiramate,[2] a unique sugar sulfamate drug, which has been marketed worldwide for the treatment of epilepsy and migraine, attaining annual sales of more than $2 billion.[3] Topiramate is also a principal component of the antiobesity drug Qsymia.[4] Maryanoff is an internationally renowned expert in drug design and drug discovery, especially in the application of protein structure-based drug design. He made seminal contributions to understanding the stereochemistry and mechanism of the Wittig reaction; adapted the cobalt-catalyzed alkyne trimerization to the synthesis of macrocycles; and devised novel peptides that undergo self-assembly to mimic native collagen structurally and functionally. Maryanoff is an author on 280 scientific publications, including several books (editor), book chapters, and review articles. He is an inventor on 100 issued U.S. patents, has presented over 185 invited lectures worldwide, and mentored 11 postdoctoral associates. Maryanoff organized and edited a special memorial issue of the Journal of Medicinal Chemistry to honor the memory of Dr. Paul Janssen (2005)[5] and has served on numerous editorial advisory boards for scientific journals and research grant review committees.
Awards and honors
Johnson & Johnson's Philip B. Hofmann Research Scientist Award, 1978
^US 4513006, Maryanoff, Bruce E. & Gardocki, Joseph F., "Anticonvulsant sulfamate derivatives", published 1985-04-23, assigned to McNeil Laboratories Inc.
^"The Drexel 100"(PDF), Drexel Blue & Gold, vol. 17, no. 1, pp. 24–25, June 15, 2006, archived from the original(PDF) on April 10, 2008, retrieved January 12, 2008
^Wyeth Lecture, Temple University, archived from the original on January 16, 2013, retrieved November 15, 2012